EUCTR2005-000807-33-SE进行中（未招募）不适用
Randomized, double-blind, two -arms placebo-controlled, parallel-group, multicenter study of rimonabant 20 mg once daily in the treatment of atherogenic dyslipidemia in abdominally obese patients. - ADAGIO-Lipids
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 740
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female patients aged =18 years
- •Waist circumference > 102 cm in men and > 88 cm in women
- •Dyslipidemia consisting of:
- •- Triglyceridemia = 1.50g/L (i.e. 1.69mmol/L) and = 7.0g/L (i.e. 7.90mmol/L)
- •- HDL cholesterol < 50mg/dL (1.29mmol/L) in women and < 40mg/dL (1.04mmol/L)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Weight change > 5 kg within 3 months prior to screening visit
- •Pregnancy or lactation, or women planning to become pregnant
- •Absence of medically approved contraceptive methods for females of childbearing
- •Marijuana or hashish users
- •Presence of any other condition (e.g. geographic, social…) actual or anticipated, that
- •the Investigator feels that would restrict or limit the subject’s participation for the
- •duration of the study.
研究者
相似试验
进行中（未招募）
不适用
Randomized, double-blind, two -arms placebo-controlled, parallel-group, multicenter study of rimonabant 20 mg once daily in the treatment of atherogenic dyslipidemia in abdominally obese patients. - ADAGIO-LipidsEUCTR2005-000807-33-DKsanofi-aventis recherche & développement740
进行中（未招募）
2 期
The effects of Muno-IgYTM on immune function in healthy adult volunteersISRCTN51932144IGY Immune Technologies & Life Sciences, Inc.28
招募中
3 期
Clinical Trial of Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19CTRI/2020/05/025277Cadila Pharmaceuticals Limited
进行中（未招募）
不适用
A randomized, double blind, two-arms placebo-controlled, parallel group, multicenter study of rimonabant 20 mg once daily in the treatment of atherogenic dyslipidemia in abdominally obese patientsAbdominally obese patients with atherogenic dyslipidemiaMedDRA version: 6.1Level: HLTClassification code 10014486EUCTR2005-000807-33-ITSANOFI-SYNTHELABO740
招募中
3 期
Safety and Efficacy of Beta Amyrin Palmitate in newly diagnosed patients of type 2 diabetes mellitus associated with dyslipidaemia.CTRI/2023/09/058019Sam Sabinsa Group Limited